QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

HC Wainwright & Co. analyst Andrew S. Fein assumes MetaVia (NASDAQ:MTVA) with a Buy rating and announces Price Target of...

Core News & Articles

MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16...

Core News & Articles

Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential ofMetaVia's Oral GPR119 Ag...

Core News & Articles

Top-Line Data Expected in the Fourth Quarter of 2025CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), ...

Core News & Articles

-SEC Filing

Core News & Articles

https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_05222025_MTVA_Bautz.pdf

Core News & Articles

Maxim Group analyst Jason McCarthy maintains MetaVia (NASDAQ:MTVA) with a Buy and lowers the price target from $6 to $3.

Core News & Articles

MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.51) by 29...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION